MET and hepatocellular carcinoma: This study indicated that miR-93 is a novel regulator of the oncogenic c-Met/PI3K/Akt pathway in HCC, and inhibition of miR-93 hinders tumorigenesis and enhances sensitivity to conventional chemotherapy and tyrosine kinase inhibitor treatment.